Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.

While investors fixate on slowing elective surgeries, a powerful, non-obvious growth engine is accelerating inside the company’s U.S. business.

If you’ve watched Intuitive Surgical (ISRG) stock lately, you might be feeling cautious. The shares are down 26% over the last year, significantly trailing the broader market. Skeptics have a clear and reasonable case: they point to a 10% decline in U.S. bariatric procedures, a direct hit from the rise of GLP-1 weight-loss drugs, and persistent challenges in key overseas markets like China and Japan.

The market seems to have priced in a story of slowing growth in scheduled, elective surgeries. But one number, tucked away in the company’s results, suggests a different engine is just starting to rev. That number is the growth in U.S. after-hours procedures.

In the most recent quarter, these procedures grew 31% year-over-year.

What Exactly Is This After-Hours Business?

This isn’t about surgeons working late on knee replacements. Management has clarified that “after-hours” is a proxy for acute care — think certain common emergency surgeries and cholecystectomies (gallbladder removals). These are non-elective, urgent procedures. For years, the da Vinci robot was synonymous with complex, planned surgeries in urology and gynecology. This 31% growth figure is hard evidence that the platform is successfully expanding into a completely different and more resilient category of care.

The mechanism here is powerful. Every new procedure, especially in an untapped area like acute care, drives overall system utilization. Higher utilization makes the half-million-dollar-plus robots more economical for hospitals, justifying future purchases. More importantly, it directly fuels Intuitive’s high-margin recurring revenue stream from the sale of single-use instruments and accessories required for each surgery.

How This Answers The Biggest Worry

The concern over GLP-1 drugs is real, but it’s a threat to a specific category of elective surgery. The growth in after-hours procedures, however, is almost entirely non-elective. People do not schedule a common type of emergency surgery. This expansion into acute care provides a new, durable growth vector that is structurally insulated from the trends affecting weight-loss surgeries.

It demonstrates that the da Vinci platform’s versatility extends beyond meticulously scheduled operating theaters, proving its value in the high-pressure, unpredictable environment of an emergency room. While the stock’s trailing price-to-earnings multiple of 47.9 is far from cheap, it sits comfortably within its 10-year range of 33.2 to 90.7, suggesting the price gives little credit for this new avenue of growth.

The risks in international markets and bariatrics haven’t vanished. But the rapid expansion into acute care shows the company is opening new fronts faster than skeptics may realize. The key thing to watch now is whether this after-hours growth continues to push overall U.S. system utilization higher, proving this new engine has staying power.

How To Hold A Bet Like This Without Betting The Farm

Step back for a second. What you just read was the result of real work, separating the one number that matters from the noise and pressure-testing whether the strength behind it actually holds. That is the difference between a hunch and an edge, and almost no one has the time to do it on every name they own.

That research is what the Trefis High Quality (HQ) Portfolio does for a living, across 30 quality businesses, rebalanced with discipline so no single name carries an outsized share of your outcome. A strong case is still one case, and a rules-based basket of them beats staking everything on a single volatile name. The portfolio has outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. If an edge like this is worth acting on, a disciplined home for quality is worth a serious look.